Pharmaceuticals company Eris Lifesciences announced Q3FY25 results Q3FY25 consolidated operating revenue up by 50% to Rs 727 crore. Q3FY25 Margin and Fixed Cost Synergies. Gross Margin down by 604 bps due to significant changes in product/ business mix. Fixed Expenses (% of Revenue) down 436 bps YoY. Q3FY25 EBIDTA Rs 250 crore - YoY growth of 43%. Amortisation and Finance costs reflect the full impact of all acquisitions made till date. Book Tax Rate - 25.2% in Q3FY25. OCF-to-EBIDTA ratio - 120% in Q3FY25. Result PDF
Pharmaceuticals company Eris Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 consolidated operating revenue up by 47% to Rs 741 crore and H1 up by 50% to Rs 1,461 crore. Q2FY25 Margin and Fixed Cost Synergies. Gross Margin down by 641 bps due to significant changes in product/ business mix. Fixed Expenses (% of Revenue) down 625 bps YoY. EBIDTA Margin (35.7%) in-line with Q2FY24 on account of fixed cost synergies coming in. Q2 EBIDTA Rs 265 crore - YoY growth of 46%. H1 EBIDTA Rs 515 crore - YoY growth of 47%. Amortisation and Finance costs reflect the full impact of all acquisitions made till date. Q2 book tax rate - 25% of PBT; cash tax rate 22%. OCF-to-EBIDTA ratio is 119% in Q2 and 94% in H1. Cash EPS - Rs 20 in H1FY25, same as in H1FY24. Result PDF